IN8bio, Inc (INAB) Prices $46.9M Placement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- S&P 500, Nasdaq edge higher as chips recover; megacap earnings in focus
- Oil steadies as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- S&P 500, Nasdaq edge higher as chips recover; megacap earnings in focus
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Oil steadies as hopes of renewed US-Iran negotiations offset Houthi threat
- IREN raises 2026 revenue target to $4bn after $2.8bn in contracts
IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement
December 11, 2023 9:00 AM ESTInitial closing of $14.4 million to support operational execution and extend cash runway into 2025 with potential for up to $32.5 million in additional capital at increasing valuations
Proceeds to help accelerate advancement of the Companys gamma-delta T cell therapies
NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that it has entered into a securities purchase agreement with certain healthcare-focused institutional investors to raise up to $46.9 million at increasing... More
